CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
6.79
+0.22 (3.35%)
At close: Aug 13, 2025, 4:00 PM
6.92
+0.13 (1.91%)
Pre-market: Aug 14, 2025, 8:34 AM EDT
CNS Pharmaceuticals Employees
As of December 31, 2024, CNS Pharmaceuticals had 5 total employees, including 3 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,122,875
Market Cap
3.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CNSP News
- 23 days ago - CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - Accesswire
- 27 days ago - CNS Pharmaceuticals Announces Reverse Stock Split - Accesswire
- 5 weeks ago - CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment - Accesswire
- 7 weeks ago - CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 - Accesswire
- 2 months ago - CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit - Accesswire
- 3 months ago - CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 3 months ago - CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 3 months ago - CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Accesswire